Related Experiment Video
Updated: Jul 3, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Biologic agents in the management of inflammatory eye diseases
1Macular Research Unit, Centre for Eye Research Australia, 32 Gisborne Street, University of Melbourne, East Melbourne, Victoria 3002, Australia.
Abstract:
Biologics are a new class of drugs that comprise recombinant cytokines and monoclonal antibodies directed against selected cell-surface markers. They include the tumor necrosis factor-alpha inhibitors infliximab, etanercept, and adalimumab; the antilymphocyte drugs rituximab and alemtuzumab; the interleukin-2 receptor blocker daclizumab; and recombinant interferon-alpha. This article reviews the rationale and current evidence for their use in uveitis, scleritis, and orbital inflammation.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Microbiome of the Eye
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Ophthalmic Drug Delivery Systems